QTc shortening with a new investigational cancer drug: a brief case study
{{output}}
Introduction: BAY-79 is an inhibitor of receptor tyrosine kinases with high selectivity versus other kinases. Species scaling, complicated by nonlinear pharmacokinetics, predicted a C(max.u) of 36-178nmol/L at the human efficacio... ...
